Global Bakery Expo Spotlight: Angel Yeast Launches Feravor™ - A Revolutionary Natural Flavor Solution for Clean-Label Baking
SHANGHAI and DUSSELDORF, Germany, May 20, 2025 /PRNewswire/ -- At Europe's IBA 2025 and Asia's China Bakery Exhibition, Angel Yeast (SH600298) captured global attention with its groundbreaking Feravor™ series. This innovative flavored yeast solution, available in Floral-Fruity and Butter variants, empowers bakers to meet clean-label demands with natural, flavor-enhancing technology.
Leveraging proprietary microbial fermentation technology, Angel Yeast's innovation simultaneously elevates flavor complexity and extends product freshness. More than just an ingredient advancement, this development represents a strategic shift toward sustainable baking practices, establishing new benchmarks for premium baked goods. By enabling bakers to develop differentiated, clean-label offerings, the technology is poised to accelerate the industry's transition to more natural and value-added production methods.
Angel Yeast showcased its innovative Feravor™ yeast series at the exhibition, featuring two natural flavor-enhancing strains: Feravor™-Rose and Feravor™-Buttery. Bread-making involves mixing, fermenting, proofing, and baking, with yeast naturally breaking down sugars to create both leavening gases and flavor compounds. Angel Yeast's Feravor™ series—specifically developed for flavored poolish production—enhances this process through patented microbial strains that intensify aroma via natural metabolic pathways, eliminating the need for additives. Compatible with all bread varieties (from European-style to Asian-style), these yeasts integrate seamlessly into existing recipes, synergize with commercial baker's yeast (including high-sugar variants), and enable bakers to elevate flavor complexity without altering production methods, directly addressing clean-label consumer demands.
"The core technology of these flavor yeasts lies in the strategic screening of target strains from traditional food sources and specialized environments, coupled with precision fermentation optimization. This enables natural aroma amplification in baked goods – achieving what artificial additives once promised, but through purely biological means," said Dr. Yafang Sun, General Manager of the Yeast and Strain Resource Technology Center at Angel Yeast.
Feravor™-Rose: A yeast strain developed by Angel Yeast through years of screening from traditional Chinese fermented foods. Through fermentation metabolism, it imparts natural aromas like rose, fruit, and brandy notes to bread. It boasts strong adaptability, making it applicable to various bread formulas. Moreover, its natural antimicrobial metabolites can extend the product's shelf life, meeting premium demands for naturally flavored baked goods.
Feravor™-Buttery: A yeast strain developed by Angel Yeast through years of screening from plateau dairy products. Through fermentation metabolism, it imparts natural butter aroma and fresh floral notes to bread. Its fast-acting properties suit time-sensitive baking operations, preserving dough softness in 48-hour cold proofs and improving crumb moisture in sugar-free breads.
As demand grows for healthier, natural foods, Angel Yeast's response is its Feravor™ series – breakthrough microbial technology overcoming traditional yeast's flavor limitations. The floral-fruity and buttery strains deliver authentic fermentation flavors while maintaining baking efficiency, empowering artisanal bakers with clean-label solutions. In the future, Angel Yeast will continue advancing sustainable baking through natural flavor innovations, redefining industry standards for quality and environmental stewardship.
View original content to download multimedia:https://www.prnewswire.com/news-releases/global-bakery-expo-spotlight-angel-yeast-launches-feravor--a-revolutionary-natural-flavor-solution-for-clean-label-baking-302460608.html
SOURCE Angel Yeast
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Securonix Acquires ThreatQuotient to Deliver Industry's Broadest and Deepest Threat Detection Investigation and Response
PLANO, Texas--(BUSINESS WIRE)--Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of ThreatQuotient, a four-time leader in threat intelligence based on QKS Group Spark Matrix report and the force behind ThreatQ, the most innovative external threat intelligence platform. This combination will create a comprehensive, modular, and fully integrated AI-driven platform for threat detection, investigation, and response (TDIR), leveraging advanced analytics and insights across both internal and external threats. This acquisition accelerates the modernization of security operations by uniting internal and external threat intelligence with real-time analytics and agentic AI. Unlike external threat intelligence bolt-on solutions with disconnected management interfaces, the integrated platform from Securonix and ThreatQuotient will deliver unified visibility, faster response, and greater operational clarity. "Bringing threat intelligence management and SIEM together in a unified platform is a game changer. We've already seen the value of deeply enriched advanced analytics and detection in our Securonix SIEM environment—but coupling that with integrated threat curation, prioritization, and response should help customers move even faster. It means fewer swivel-chair investigations, more accurate triage, and greater confidence that security analysts are working with the most relevant threats. This kind of integration has the potential to accelerate the ability to detect, respond, and stay ahead," said Marcel Jonker, Director of Cybersecurity Operations at Cambia Health Systems. The integration of Securonix and ThreatQuotient promises to deliver up to a 70% reduction in Mean Time to Respond (MTTR), enabling security teams to detect, investigate, and remediate threats significantly faster. By combining curated threat intelligence with AI-driven automation, the solution will deliver exponential improvements in filtering out false positives, enriching alerts with actionable context, and automating historical threat sweeps and incident response. This reduces alert overload, speeds up root cause analysis, and minimizes manual handoffs—cutting investigation time from hours to minutes and enabling automated containment before threats escalate. 'Security teams are drowning in noise and struggling to keep up with evolving threats,' said Kash Shaikh, CEO and President of Securonix. 'This acquisition brings together Securonix's Agentic AI-driven Platform with ThreatQuotient's deep threat intelligence to deliver clarity, speed, and automated workflows to our customers, reducing false positives by up to 90%. Together, we're building the modern SOC Platform—proactive, intelligent, and built for what's next.' Kash added, 'Securonix and ThreatQuotient bring together complementary strengths—deep innovation across internal and external threat domains, and a shared commitment to innovation and customer service. Both companies serve enterprise and government customers as well as managed security service providers (MSSPs), and we're excited to welcome the talented ThreatQuotient team and their customers to Securonix.' Purpose-Built for Analysts. Proven Against Real-World Threats. ThreatQuotient's Threat Intelligence Platform (TIP) strength lies in delivering curated, contextualized threat intelligence that drives smart, timely decisions. When combined with Securonix's EON Agentic AI-based SIEM, SOAR, UEBA and Data Pipeline Manager, customers can accelerate their migration from reactive threat hunting-based defense to proactive, real-time, behavior-driven, open-agentic security operations. With this integration, Securonix customers and partners will enjoy the following benefits: Gain clear visibility: Integrate deep enriched real-time analytics from Securonix with curated external intelligence from ThreatQuotient to create a single, high-context stream of alerts. Eliminate blind spots and accelerate threat identification with confidence. Stay ahead of risk: Auto-enrich Indicator of compromise (IoCs) and preemptively respond to repeat attacks, blocking 90 percent before they start. Act smarter: Automate repetitive tasks, reduce false positives, and streamline investigations. Teams can stay focused on high-priority threats and reduce time spent on manual triage. Deploy your way: Continue to use ThreatQ as a standalone threat intelligence platform or as part of the fully integrated Securonix solution. Deploy on-premise or SaaS in a way that fits the current architecture and scales with needs. Accelerated Roadmap: Combined R&D synergies will accelerate upcoming roadmap innovations, including Agentic AI and ThreatQuotient's innovation priorities. With this acquisition, ThreatQuotient customers and partners will enjoy the following benefits: Increased Scale: ThreatQ customers can take advantage of Securonix's global R&D scale and GTM reach, including access to Securonix's Threat Labs Intelligence. Deeper Integrations: Gain access to an enriched roadmap and integration between Securonix's best-in-class SIEM, SOAR, and UEBA portfolio and ThreatQ, including extension of Agentic AI advancements. Continued Focus: Zero interruption of their existing service, as ThreatQuotient will continue to operate as a standalone offering, with no disruption to existing roadmap and workflows. 'Enterprises, government institutions and managed security service providers rely on ThreatQuotient to protect their mission critical businesses. Joining Securonix marks a powerful new chapter for ThreatQuotient. By uniting our strengths, we can accelerate innovation, expand our reach, and deliver greater value to our customers. I'm proud of what we've built and excited for what's ahead,' said John Czupak, CEO of ThreatQuotient. BTIG, LLC served as exclusive financial advisor, and King & Spalding LLP served as legal advisor to ThreatQuotient. Vinson & Elkins LLP served as legal advisor to Securonix. About Securonix Securonix is leading the transformation of cybersecurity with the industry's first Unified Defense SIEM powered by agentic AI, purpose-built to decide and act across the threat lifecycle with a human-in-the-loop philosophy. Built for scale, precision, and speed, our cloud-native platform empowers global enterprises to shift from reactive security to proactive, autonomous operations. Recognized as a Leader in the Gartner® Magic Quadrant™ for SIEM and a Customers' Choice by Gartner Peer Insights™, Securonix is driving the next era of intelligent, autonomous security operations. Learn more at About ThreatQuotient ThreatQuotient improves security operations by fusing disparate data sources, tools, and teams to accelerate threat detection, investigation, and response (TDIR). ThreatQ is the first purpose-built, data-driven threat intelligence platform that helps teams prioritize, automate, and collaborate on security incidents; enables more focused decision-making; and maximizes limited resources by integrating existing processes and technologies into a unified workspace. The result is reduced noise, clear priority threats, and the ability to automate processes with high-fidelity data. ThreatQuotient's leading integration marketplace, data management, orchestration, and automation capabilities support multiple use cases including threat intelligence management and sharing, incident response, threat hunting, spear phishing, alert triage, and vulnerability management. For more information, visit
Yahoo
2 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Synthetic Identity Document Fraud Surges 300% in the U.S. - Sumsub Warns E-Commerce, Healthtech and Fintech at Risk
North America sees major spike in synthetic document fraud and deepfake-related attacks, particularly across e-commerce, edtech, and healthtech sectors NEW YORK, June 12, 2025 /PRNewswire/ -- Sumsub, a global leader in verification, today released Q1 2025 identity fraud trends based on internal data, revealing a dramatic rise in AI-enabled fraud across the United States. According to platform data, deepfake fraud has surged by 1100%, while synthetic identity document fraud rose by over 300% with attackers exploiting generative AI to create fake passports, IDs, and biometric data. Sumsub analyzed millions of verification checks conducted on its platform between January and March 2025 across industries such as fintech, e-commerce, healthtech, and edtech to uncover emerging fraud trends. One of the most pressing concerns is the rise of synthetic identity document fraud, where criminals use AI tools to generate fake identity documents such as driver's licenses or passports. These synthetic identity documents are often realistic enough to bypass basic KYC checks, posing a significant challenge for businesses. Unlike synthetic identity documents, which involve the creation of entirely fake personas using a mix of real and fabricated data, synthetic identity documents refer specifically to falsified documents or images generated by AI. Fraudsters then use these AI-generated visuals to open accounts, conduct illicit transactions, or bypass compliance processes, making detection increasingly difficult without advanced verification tools North America-Specific Insights (Q1 2025): Synthetic identity document fraud spiked by 311% in North America compared to Q1 2024, making it the region's most alarming growth vector. Deepfake fraud jumped by 1100%, marking a clear signal that generative AI is being used to bypass facial recognition and biometric checks. High fraud activity was recorded in e-commerce, healthtech and edtech––industries have seen accelerated digitization post-pandemic. The U.S. in particular saw a sharp increase in fintech fraud attempts, underscoring the need for real-time, multi-layered fraud prevention solutions. Key Global Findings (Q1 2025): Synthetic identity document fraud is rising across all regions, fueled by widespread access to GenAI tools that can generate highly realistic fake IDs. Top markets for synthetic identity document fraud include: Ethiopia (2.17%) Pakistan (2.08%) Nigeria (1.52%) Other notable markets: Hong Kong (0.99%), Indonesia (0.84%), Turkey (0.80%)Deepfake-related attacks are growing globally, particularly to bypass biometric systems—now one of the fastest-evolving fraud vectors. Healthtech fraud attempts rose by 384%, signaling its emergence as a high-value target alongside fintech and e-commerce. Regional deepfakefraud surges: Canada: 3,400% Hong Kong: 1,900% Singapore: 1,500% Mainland China: 1,183% Germany: 1,100% United Kingdom: 900% United States: 700% "The pace at which fraud tactics are evolving is staggering," said Andrew Sever, CEO of Sumsub. "As generative AI becomes more accessible, so does the ability to generate synthetic identity documents and deepfakes at scale. What we're seeing is a broader trend, in which Fraud-as-a-Service is becoming a reality, where malicious actors can easily access sophisticated tools to carry out attacks. Businesses can no longer rely on outdated verification tools. It's imperative they adopt an intelligent, adaptive approach to stay ahead." To combat this new wave of fraud, Sumsub continues to invest in advanced AI-powered fraud detection, document authenticity analysis, and biometric defense tools to protect businesses and users worldwide. The company urges organizations to stay proactive by integrating multi-layered verification and continuous monitoring into their onboarding and transaction workflows. About Sumsub: Sumsub is a full-cycle verification and ongoing monitoring platform that secures the whole user journey. With Sumsub's customizable KYC, KYB, Transaction Monitoring, Fraud Prevention and Travel Rule solutions, you can orchestrate your verification process, welcome more customers worldwide, meet compliance requirements, reduce costs, and protect your business. Sumsub has over 4,000 clients across the fintech, crypto, transportation, trading, edtech, e-commerce and gaming industries including Duolingo, Bitpanda, Wirex, Avis, Bybit, Vodafone, Kaizen Gaming, and TransferGo. Methodology Note: Unless otherwise specified, all figures referenced are based on Sumsub's internal statistics, drawn from millions of identity verification checks conducted globally between Q1 2024 and Q1 2025. These insights reflect real-world patterns across multiple industries and geographies, offering a representative snapshot of digital verification trends during this period. View original content to download multimedia: SOURCE Sumsub Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
